Clin Cancer Res 1999, 5:343–353.PubMed 19. Zhang L, Hung MC: Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 1996, 12:571–576.PubMed 20. Lonafarnib Jayasuriya H, Koonchanok NM, Geahlen RL, McLaughlin JL, Chang CJ: Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum. J Nat Prod 1992, 55:696–698.CrossRefPubMed 21. Lu Y, Zhang J, Qian J: The effect of emodin
on VEGF receptors NF-��B inhibitor in human colon cancer cells. Cancer Biother Radiopharm 2008, 23:222–228.CrossRefPubMed 22. Chang LC, Sheu HM, Huang YS, Tsai TR, Kuo KW: A novel function of emodin: enhancement of the nucleotide excision repair of UV- and cisplatin-induced DNA damage in human cells. Biochem Pharmacol 1999, 58:49–57.CrossRefPubMed 23. Yim H, Lee YH, Lee CH, Lee SK: Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor.
Planta Med 1999, 65:9–13.CrossRefPubMed 24. Leslie AG: Integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 1999, 55:1696–1702.CrossRefPubMed selleck inhibitor 25. Collaborative Computational Project, Number 4: The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994, 50:760–763.CrossRef 26. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL: Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998, 54:905–921.CrossRefPubMed 27. Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004, 60:2126–2132.CrossRefPubMed 28. Morris AL, MacArthur MW, Hutchinson EG, Thornton JM: Stereochemical quality of protein structure coordinates. Proteins 1992, 12:345–364.CrossRefPubMed 29. Sharma SK, Kapoor M, Ramya TN, Kumar Etofibrate S, Kumar G, Modak R, Sharma S, Surolia N, Surolia A: Identification,
characterization, and inhibition of Plasmodium falciparum beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ). J Biol Chem 2003, 278:45661–45671.CrossRefPubMed 30. Tasdemir D, Lack G, Brun R, Ruedi P, Scapozza L, Perozzo R: Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem 2006, 49:3345–3353.CrossRefPubMed 31. Osato MS: Antimicrobial susceptibility testing for Helicobacter pylori : sensitivity test results and their clinical relevance. Curr Pharm Des 2000, 6:1545–1555.CrossRefPubMed 32. Lu YJ, White SW, Rock CO: Domain swapping between Enterococcus faecalis FabN and FabZ proteins localizes the structural determinants for isomerase activity. J Biol Chem 2005, 280:30342–30348.CrossRefPubMed 33.